FibroGen Inc

10.80+0.0600+0.56%Vol 806.70K1Y Perf -74.69%
Sep 24th, 2021 16:00 DELAYED
BID10.07 ASK10.90
Open10.69 Previous Close10.74
Pre-Market- After-Market10.80
 - -  - -%
Target Price
24.33 
Analyst Rating
Moderate Buy 1.86
Potential %
125.28 
Finscreener Ranking
★+     43.97
Insiders Trans % 3/6/12 mo.
100/-33/-89 
Value Ranking
★+     43.82
Insiders Value % 3/6/12 mo.
100/-71/-98 
Growth Ranking
★+     41.84
Insiders Shares Cnt. % 3/6/12 mo.
100/-45/-93 
Income Ranking
 —    -
Price Range Ratio 52W %
1.92 
Earnings Rating
Strong Sell
Market Cap1.00B 
Earnings Date
4th Nov 2021
Alpha-0.00 Standard Deviation0.17
Beta0.92 

Today's Price Range

10.6010.90

52W Range

9.8957.21

5 Year PE Ratio Range

-31.40-20.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.61%
1 Month
-9.01%
3 Months
-60.97%
6 Months
-65.52%
1 Year
-74.69%
3 Years
-82.12%
5 Years
-51.26%
10 Years
-

TickerPriceChg.Chg.%
FGEN10.800.06000.56
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
2.30
2.40
0.27
0.40
-81.70
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
93.40
-132.90
-120.90
-62.40
-60.13
RevenueValueIndustryS&P 500US Markets
171.82M
1.86
-0.39
4.13
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.48-1.45-202.08
Q01 2021-0.90-0.7813.33
Q04 2020-0.29-0.64-120.69
Q03 2020-0.890.35139.33
Q02 2020-0.59-0.95-61.02
Q01 2020-0.30-0.89-196.67
Q04 2019-0.62-1.12-80.65
Q03 2019-0.59-0.573.39
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.05-138.46Negative
12/2021 QR-0.68-2 366.67Negative
12/2021 FY-2.75-172.28Negative
12/2022 FY-2.39-16.59Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.05
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume806.70K
Shares Outstanding92.62M
Shares Float81.61M
Trades Count9.25K
Dollar Volume43.52M
Avg. Volume1.38M
Avg. Weekly Volume1.31M
Avg. Monthly Volume1.43M
Avg. Quarterly Volume1.62M

FibroGen Inc (NASDAQ: FGEN) stock closed at 10.8 per share at the end of the most recent trading day (a 0.56% change compared to the prior day closing price) with a volume of 806.96K shares and market capitalization of 1.00B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 531 people. FibroGen Inc CEO is Enrique A. Conterno.

The one-year performance of FibroGen Inc stock is -74.69%, while year-to-date (YTD) performance is -70.88%. FGEN stock has a five-year performance of -51.26%. Its 52-week range is between 9.89 and 57.21, which gives FGEN stock a 52-week price range ratio of 1.92%

FibroGen Inc currently has a PE ratio of -4.60, a price-to-book (PB) ratio of 4.16, a price-to-sale (PS) ratio of 6.08, a price to cashflow ratio of 12.50, a PEG ratio of 2.32, a ROA of -27.86%, a ROC of -56.94% and a ROE of -68.22%. The company’s profit margin is -60.13%, its EBITDA margin is -120.90%, and its revenue ttm is $171.82 Million , which makes it $1.86 revenue per share.

Of the last four earnings reports from FibroGen Inc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. FibroGen Inc’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for FibroGen Inc is Moderate Buy (1.86), with a target price of $24.33, which is +125.28% compared to the current price. The earnings rating for FibroGen Inc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

FibroGen Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

FibroGen Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 22.19, ATR14 : 0.62, CCI20 : -135.68, Chaikin Money Flow : -0.01, MACD : -0.68, Money Flow Index : 46.52, ROC : -10.00, RSI : 35.60, STOCH (14,3) : 32.97, STOCH RSI : 0.76, UO : 45.93, Williams %R : -67.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of FibroGen Inc in the last 12-months were: Elias Kouchakji (Option Excercise at a value of $103 220), James A. Schoeneck (Option Excercise at a value of $117 300), K. Peony Yu (Sold 3 350 shares of value $139 394 ), Kalevi Kurkijarvi (Option Excercise at a value of $1 021 080), Kalevi Kurkijarvi (Sold 48 000 shares of value $2 114 637 ), Pat Cotroneo (Sold 14 242 shares of value $475 205 ), Thane Wettig (Buy at a value of $35 743), Thomas F. Kearns (Option Excercise at a value of $63 000), Thomas F. Kearns (Sold 18 000 shares of value $630 360 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (50.00 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (42.86 %)
4 (50.00 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.86
Moderate Buy
2.00
Moderate Buy
1.67

FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

CEO: Enrique A. Conterno

Telephone: +1 415 978-1200

Address: 409 Illinois Street, San Francisco 94158, CA, US

Number of employees: 531

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

51%49%

Bearish Bullish

50%50%

News

Stocktwits